Safety and efficacy of gemcitabine plus cisplatin combination in pretreated metastatic breast cancer patients.
Metastatic breast cancers (MBC) previously treated with anthracyclines (A) and taxanes (T) have a complicated management. Gemcitabine (G)-cisplatin (C) combinations have been used as synergistic salvage therapy in MBC and are considered as another option for patients with important symptoms and aggressive visceral disease. We analyzed the safety and efficacy of GC in AT-pretreated MBC, as well as overall survival (OS) and time to progression (TTP). Forty-nine subjects received IV G 750 mg/m(2) and C 30 mg/m(2), both d1 and d8 every 3 weeks. Response evaluation was performed every second cycle and in the end of treatment. GC protocol was the first-line palliative chemotherapy in half of the cases, and median number of cycles/patient were 4(2-12). Lung (75.5%) was the most frequent site of metastasis. Most of the patients related clinical improvement with chemotherapy with minimal/mild tolerable collateral effects in 85.7% of cases. Following 34 months, mean OS/TTP was 13.12/6.6 months. Objective-responded patients (40.3%) were statistically associated with the improvement in symptoms after CT (P < 0.01), and OS was directly correlated with chemotherapy response (P < 0.01). HER-2 overexpression was a prognostic factor with reduced OS (P = 0.01). GC protocol was effective and tolerable in objective-responded patients.
Department of Gynecology and Obstetrics, School of Medicine of Ribeirão Preto, São Paulo University, Avenida Bandeirantes 3900, 8th Floor, Ribeirão Preto, SP 14048-900, Brazil. lgobrito@gmail.com
Luiz Gustavo Oliveira
LG
Brito
Jurandyr Moreira
JM
de Andrade
Thiago
T
Lins-Almeida
Fábio Eduardo
FE
Zola
Mariana Novaes
MN
Pinheiro
Heitor Ricardo Cosiski
HR
Marana
Daniel Guimarães
DG
Tiezzi
Fernanda Maris
FM
Peria
D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D001943:Breast Neoplasms / Q000188:drug therapy* / Q000401:mortality* / Q000473:pathology; D002945:Cisplatin / Q000008:administration & dosage / Q000009:adverse effects; D003841:Deoxycytidine / Q000008:administration & dosage / Q000009:adverse effects / Q000031:analogs & derivatives; D005260:Female; D006801:Humans; D053208:Kaplan-Meier Estimate; D008875:Middle Aged; D009362:Neoplasm Metastasis / Q000188:drug therapy; D009367:Neoplasm Staging; D012189:Retrospective Studies; D016879:Salvage Therapy / Q000379:methods*; D018709:Statistics, Nonparametric; D016896:Treatment Outcome; D000093542:Gemcitabine
D003841:Deoxycytidine; D002945:Cisplatin; D000093542:Gemcitabine
Chemotherapy. 2009;55(3):155-60
19390188
Invest New Drugs. 2008 Aug;26(4):363-8
18165864
J Clin Oncol. 2000 Jun;18(11):2245-9
10829044
Clin Cancer Res. 2000 Mar;6(3):773-81
10741696
Invest New Drugs. 2010 Dec;28(6):859-65
19705063
J Clin Oncol. 1998 Aug;16(8):2659-71
9704716
Cancer Chemother Pharmacol. 2007 Feb;59(2):269-74
16763791
J Egypt Natl Canc Inst. 2004 Mar;16(1):8-14
15716992
Clin Cancer Res. 1996 Mar;2(3):521-30
9816199
Semin Oncol. 1995 Aug;22(4 Suppl 11):72-9
7481849
Cancer Res Treat. 2008 Jun;40(2):81-6
19688053
J Clin Oncol. 1996 Aug;14(8):2197-205
8708708
Anticancer Drugs. 2006 Jun;17(5):565-70
16702814
Clin Breast Cancer. 2002 May;3 Suppl 1:24-9
12057042
Cancer Chemother Pharmacol. 2006 May;57(5):640-6
16163537
Clin Transl Oncol. 2007 Jul;9(7):459-64
17652060
Breast Cancer Res Treat. 2008 Apr;108(3):319-31
17530427
J Clin Oncol. 2009 May 1;27(13):2163-9
19307510